Screener
Allogene Therapeutics ALLO Escrow deposit
Escrow deposit at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EscrowDeposit.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Long-term investments | — | 8,043 |
| Operating lease right-of-use asset | 38,819 | 39,888 |
| Property and equipment, net | 70,023 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 |
| Total assets | $395,958 | $415,905 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's escrow deposit?
- Allogene Therapeutics (ALLO) reported escrow deposit of $0 in Q1 2026.
- How has Allogene Therapeutics's escrow deposit changed year-over-year?
- Allogene Therapeutics's escrow deposit decreased by 100.0% year-over-year, from $21.64M to $0.
- What does escrow deposit mean?
- This represents funds held in a third-party account as security for contractual obligations, such as lease agreements or clinical trial facility requirements. It reflects restricted cash that is not available for immediate operational use but serves as a guarantee for specific business commitments. Monitoring this balance helps assess the company's liquidity constraints and the scale of its long-term contractual obligations.
Ask your AI about Allogene Therapeutics's escrow deposit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude